Results 111 to 120 of about 94,936 (269)
Docetaxel-induced pericardial effusion
, 2017 Hypersensitivity reactions, cumulative fluid retention, and neurotoxicity are frequently seen toxicities related to docetaxel. Fluid retention may be present as edema, weight gain, or third place fluid collection. Pericardial effusion is rarely seen with
Alkan, Ali +3 more
core +1 more source
BJU International, EarlyView.Background Prostate cancer (PCa) is the second most common cancer in men. For patients with high‐volume metastatic PCa (mPCa) who are fit for docetaxel, a triplet therapy regimen consisting of androgen deprivation therapy (ADT), chemotherapy, and an androgen receptor pathway inhibitor (ARPI) is recommended.
Xiangwei Yang +7 more
wiley +1 more source
Benefit risk assessment and update on the use of docetaxel in the management of breast cancer
Cancer Management and Research, 2013 Scheryll Alken, Catherine M KellyDepartment of Medical Oncology, Mater Misericordiae University Hospital, Dublin, IrelandAbstract: The objective of this paper is to review the data supporting the use of docetaxel in the treatment of breast cancer ...
Alken S, Kelly CM
doaj
Docetaxel neuropathy: a distal axonopathy
, 1999 Docetaxel has been implicated as a causative agent in peripheral neuropathy, but pathological changes in peripheral nerve have not been described. During docetaxel treatment a 54-year-old man developed a sensorimotor polyneuropathy when the overall ...
R. Fazio +7 more
core +1 more source
First‐in‐human outpatient management of recurrent NMIBC with the Multi4 instrument
BJU International, EarlyView.Objectives To evaluate the feasibility, safety and diagnostic performance of outpatient management of recurrent non‐muscle‐invasive bladder cancer (NMIBC) under local anaesthesia using the Multi4 instrument, a series of preclinical studies were performed followed by a first‐in‐human clinical investigation.
Miden Melle‐Hannah +4 more
wiley +1 more source
Targeting hexokinase 2 to induce breast cancer cell senescence
British Journal of Pharmacology, EarlyView.Background and Purpose Hexokinase 2 (HK2) is a key enzyme linked to high tumour cell proliferation. Its inhibitors such as 3‐bromopyruvic acid (3‐BP) induce cancer cell death, highlighting HK2 modulation as potential anti‐cancer treatment. However, standard chemotherapies often cause the emergence of senescent cancer cells, which goes along with cell ...
Helmut Bischof +8 more
wiley +1 more source
Docetaxel treatment in the elderly patient with hormone refractory prostate cancer
, 2008 Victoria J SinibaldiSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MA, USAAbstract: Docetaxel is an anti-microtubular agent in the family of the taxanes, now FDA approved as first line chemotherapy for the treatment of hormone ...
Victoria J Sinibaldi
core
British Journal of Pharmacology, EarlyView.Abstract Aim Fluoropyrimidines, including 5‐fluorouracil (5‐FU) and capecitabine, are cornerstone antineoplastic agents for cancer. Case reports suggest that these drugs may be associated with an under‐recognised risk of ischaemic stroke or transient ischaemic attack (TIA).
Sophie Nguyen +12 more
wiley +1 more source
Early clinical studies with docetaxel. Docetaxel Investigators Group.
, 1995 Docetaxel has been evaluated in six phase I studies involving a total of 234 patients with a wide variety of tumour types (50% had breast or ovarian cancer).
Aapro M, Bruno R
core +1 more source
Targeting KRAS for cancer therapy
British Journal of Pharmacology, EarlyView.In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia +4 more
wiley +1 more source